Nolatrexed
Based on 2 publication(s) in Google Scholar
Nolatrexed (AG 337 free base) is a compound with antifolate activity, high oral bioavailability, and major toxicity at inhibitory doses is gastrointestinal reactions. It can be safely taken orally at specific doses for inhibition, with effects on platelets and neutrophils.
For research use only. We do not sell to patients.
- CAS No.: 147149-76-6
- Formula: C14H12N4OS
- Molecular Weight:284.34
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Nolatrexed
More
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CCRF-CEM | IC50 |
0.8 μM
Compound: 3
|
Concentration required to inhibit CCRF-CEM (human leukemia) cell lines
Concentration required to inhibit CCRF-CEM (human leukemia) cell lines
|
[PMID: 9873719] |
| CCRF-CEM | IC50 |
0.81 μM
Compound: 21
|
Inhibition of human lymphoblastic leukemia (CCRF-CEM) cell growth measured using a modification of the MTT36 colorimetric assay of Mosmann
Inhibition of human lymphoblastic leukemia (CCRF-CEM) cell growth measured using a modification of the MTT36 colorimetric assay of Mosmann
|
[PMID: 8459400] |
| GC3/MTK- | IC50 |
1 μM
Compound: 21
|
Inhibition of cellular growth in human adenocarcinoma cell line (GC3/M TK) deficient in thymidine kinase
Inhibition of cellular growth in human adenocarcinoma cell line (GC3/M TK) deficient in thymidine kinase
|
[PMID: 8459400] |
| HT-29 | IC50 |
3.7 μM
Compound: 3
|
Concentration required to inhibit HT-29 (human colon adenocarcinoma) cell lines
Concentration required to inhibit HT-29 (human colon adenocarcinoma) cell lines
|
[PMID: 9873719] |
| L1210 | IC50 |
1 μM
Compound: 21
|
Inhibition of mouse L1210 (murine leukemia) cell growth measured using a modification of the MTT36 colorimetric assay of Mosmann
Inhibition of mouse L1210 (murine leukemia) cell growth measured using a modification of the MTT36 colorimetric assay of Mosmann
|
[PMID: 8459400] |
| L1210 | IC50 |
1.1 μM
Compound: 3
|
Concentration required to inhibit L1210 (mouse lymphocytic leukemia) cell lines
Concentration required to inhibit L1210 (mouse lymphocytic leukemia) cell lines
|
[PMID: 9873719] |
| LY3.7.2C TK-/- cell line | IC50 |
1.5 μM
Compound: 3
|
Concentration required to inhibit LY3.7.2C TK-/-(mouse lymphoma, thymidine kinase deficient) cell lines
Concentration required to inhibit LY3.7.2C TK-/-(mouse lymphoma, thymidine kinase deficient) cell lines
|
[PMID: 9873719] |
Chemical Information
-
CAS No. 147149-76-6
-
Molecular Weight 284.34
-
Formula C14H12N4OS
-
SMILES
O=C1N=C(NC2=CC=C(C)C(SC3=CC=NC=C3)=C12)N
-
Synonyms
AG 337 free base
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Sci Data
High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma. [Abstract]2024 Sep 19;11(1):1024. PMID: 39300112 -
Commun Biol
Serine hydroxymethyltransferase as a potential target of antibacterial agents acting synergistically with one-carbon metabolism-related inhibitors. [Abstract]2022 Jun 23;5(1):619. PMID: 35739195
Protocols
-
Protocol for Pharmacokinetic Study
Pharmacokinetic studies quantify how an organism handles a drug over time through absorption, distribution, metabolism, and excretion, and the core experimental readout is the concentration-time profile of parent drug and, when relevant, metabolites in biological matrices such as plasma, whole blood, urine, bile, or tissue. Pharmacokinetic analysis links dose, route, exposure, clearance, half-life, distribution, bioavailability, and systemic exposure to drug efficacy and toxicity hypotheses rather than measuring a signaling pathway directly. The literature links pharmacokinetics to drug-development phenotypes by showing that drug metabolism and pharmacokinetics influence compound progression, exposure-response interpretation, safety margins, dosing strategy, and failure risk during discovery and development. DMPK science contributes to compound optimization by integrating physicochemical properties, in vitro metabolism, transporter behavior, in vivo exposure, and pharmacodynamic contex
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)